Consun Pharmaceutical Group (01681) Releases November 2025 Monthly Return on Movements in Securities

Bulletin Express12-01

Consun Pharmaceutical Group Limited announced that, as of 30 November 2025, the authorized share capital remained at 5,000,000,000 ordinary shares with a par value of HKD 0.1 each, totaling HKD 500,000,000.

The number of issued ordinary shares (excluding treasury shares) grew from 847,973,407 at the end of October 2025 to 847,983,407 by 30 November 2025. This 10,000‑share increase was attributable to share options exercised under the Share Option Scheme approved on 2 December 2013, raising HKD 32,800 in proceeds. Following this exercise, 9,122,857 share options remain outstanding under that scheme. Additionally, there were no new shares issued under the new Share Option Scheme approved on 31 May 2024.

Further disclosures indicate a total of 6,393,000 shares repurchased for cancellation as of 22 May 2025, which have not yet been cancelled. Despite this, total issued shares recorded an overall net increase of 10,000 shares during November 2025, resulting in a final tally of 847,983,407 issued shares at month-end.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1182258194?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-01 19:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182258194","market":"hk","top_or_hot":-1,"title":"Consun Pharmaceutical Group (01681) Releases November 2025 Monthly Return on Movements in Securities","media":"Bulletin Express","content":"<p>Consun Pharmaceutical Group Limited announced that, as of 30 November 2025, the authorized share capital remained at 5,000,000,000 ordinary shares with a par value of HKD 0.1 each, totaling HKD 500,000,000.</p>\n<p>The number of issued ordinary shares (excluding treasury shares) grew from 847,973,407 at the end of October 2025 to 847,983,407 by 30 November 2025. This 10,000‑share increase was attributable to share options exercised under the Share Option Scheme approved on 2 December 2013, raising HKD 32,800 in proceeds. Following this exercise, 9,122,857 share options remain outstanding under that scheme. Additionally, there were no new shares issued under the new Share Option Scheme approved on 31 May 2024.</p>\n<p>Further disclosures indicate a total of 6,393,000 shares repurchased for cancellation as of 22 May 2025, which have not yet been cancelled. Despite this, total issued shares recorded an overall net increase of 10,000 shares during November 2025, resulting in a final tally of 847,983,407 issued shares at month-end.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Consun Pharmaceutical Group (01681) Releases November 2025 Monthly Return on Movements in Securities</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nConsun Pharmaceutical Group (01681) Releases November 2025 Monthly Return on Movements in Securities\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-12-01 19:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Consun Pharmaceutical Group Limited announced that, as of 30 November 2025, the authorized share capital remained at 5,000,000,000 ordinary shares with a par value of HKD 0.1 each, totaling HKD 500,000,000.</p>\n<p>The number of issued ordinary shares (excluding treasury shares) grew from 847,973,407 at the end of October 2025 to 847,983,407 by 30 November 2025. This 10,000‑share increase was attributable to share options exercised under the Share Option Scheme approved on 2 December 2013, raising HKD 32,800 in proceeds. Following this exercise, 9,122,857 share options remain outstanding under that scheme. Additionally, there were no new shares issued under the new Share Option Scheme approved on 31 May 2024.</p>\n<p>Further disclosures indicate a total of 6,393,000 shares repurchased for cancellation as of 22 May 2025, which have not yet been cancelled. Despite this, total issued shares recorded an overall net increase of 10,000 shares during November 2025, resulting in a final tally of 847,983,407 issued shares at month-end.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01681","symbol_name":"康臣药业","start_time":0,"source_url":"","article_id":"1182258194","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182258194","pubTimestamp":1764588371,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Consun Pharmaceutical Group Limited announced that, as of 30 November 2025, the authorized share capital remained at 5,000,000,000 ordinary shares with a par value of HKD 0.1 each, totaling HKD...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01681":"康臣药业"},"translate_title":"康臣药业集团(01681)发布2025年11月证券变动月报表","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01681":1},"content_text":"Consun Pharmaceutical Group Limited announced that, as of 30 November 2025, the authorized share capital remained at 5,000,000,000 ordinary shares with a par value of HKD 0.1 each, totaling HKD 500,000,000.\nThe number of issued ordinary shares (excluding treasury shares) grew from 847,973,407 at the end of October 2025 to 847,983,407 by 30 November 2025. This 10,000‑share increase was attributable to share options exercised under the Share Option Scheme approved on 2 December 2013, raising HKD 32,800 in proceeds. Following this exercise, 9,122,857 share options remain outstanding under that scheme. Additionally, there were no new shares issued under the new Share Option Scheme approved on 31 May 2024.\nFurther disclosures indicate a total of 6,393,000 shares repurchased for cancellation as of 22 May 2025, which have not yet been cancelled. Despite this, total issued shares recorded an overall net increase of 10,000 shares during November 2025, resulting in a final tally of 847,983,407 issued shares at month-end.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1182258194","isCrawlerRequest":true}